Mesane Kanserli Hastalarda CTLA-4 Geni +49 A/G PolimorŞzminin Araştırılması
Küçük Resim Yok
Tarih
2017
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
İmmünoglobulin süper ailesinin bir üyesi olan sitotoksik T--lenfosit antijeni (CTLA--4), aktive hücreleri tarafından eksprese edilen bir uyarıcı moleküldür. Son yıllarda ya-- prlan çalışmalarda, CTLA--4 antijenindeki fonksiyon bozukluğunun çeşitli hastalıklara (behçet hastalığı, diyabet, Graves hastalığı ve sistemik lupus eritematozus) yol açtığı tespit edilmiştir. Ay-- rıca CTLA--4 geni ile çeşitli kanserler (meme kanseri, osteosarkom ve servikal kanser) arasında bir ilişki olabileceği de ileri sürülmüştür. Bu çalışmada, CTLA--4 geni +49 A/G polimorfizminin (rs231775) mesane kanseri hastalar için bir risk faktörü olarak değerlendirilip değerlendirileme-- yeceği araştırıldı. Gereç ve Yöntemler: Yaş dağılımı benzerlik gösteren, mesane kanserli 69 hasta (62,07 10,48 yıl) ile kontrol grubu olarak sağlıklı 149 gönüllü kişi (61,54 14,43 yıl) çalışmaya dahil edilmiştir. Hasta ve kontrol grubu kişilerde genotip analizi yapmak için polimeraz zincir re-- aksiyonu ile sınırlı parça uzunluk polimorfizm analizi kullanıldı. Veriler, ki-- kare ve Hardy--We-- inberg testleri ile analiz edildi. Hardy--Weinberg testi genotip frekansının dağılımları için kullanıldı. Bulgular: Mesane kanserli hastalarda ve kontrol grubunda, CTLA--4 geni +49 A/G po-- limorfizminde, AA genotipi sırasıyla 41 (%60, hastalarda), 81 (%55, kontrolde), AG genotipi 23 (%33), 54 (%36) ve GG genotipi (%7), 14 (%9) olarak bulunmuştur. GG genotipinin, hastalarda kontrole göre bir düşüş gösterdiği, fakat istatistiksel olarak anlamlı olmadığı tespit edilmiştir (p: 0,52). Sonuç: Sonuç olarak, mesane kanserli hastalarında, CTLA--4 geni +49 A/G polimorfizminin genotip ve allel frekanslarının kontrol grubuna göre istatistiksel olarak anlamlı farklı olmadığı be-- lirlenmiştir.
Cytotoxic T—lymphocyte antigen (CTLA—4) is member of the im— munoglobulin superfamily. This stimulator molecule is expressed by active cells. Recent studies have determined that dysfunction of CTLA—4 antigen leads to various diseases (Behçet's disease, diabetes, Graves' disease and systemic lupus erythematosus). It has also been suggested that there may be relationship between the CTLA—4 gene and various cancers (breast cancer, osteosarcoma, and cervical cancer). In this study, It was investigated whether the CTLA—4 gene +49 A/G (rs231775) polymorphism could be assessed as risk factor for bladder cancer patients. Material and Methods: This study included 69 patients with bladder cancer (62.07 10.48 years) with similar age distribution and 149 healthy control (61.54 14.43 years). Genotypes were determined by the polymerase chain reaction restriction fragment length polymorphism (PCR—RFLP) method. Data was analysed using the Chi—square test and Hardy—Weinberg test. The Hardy—Weinberg equilib— rium test was used to test the distributions of genotype frequency. Results: AA genotype was found in 41 (60%, in patients), 81 (55%, in control), AG genotype 23 (33%), 54 (36%) and GG genotype (7%), 14 (9%) respectively in patients with bladder cancer and in healthy control groups. The frequency of GG genotype in patients was less than controls, but there was no statistically signif— icant difference in the frequencies of GG genotype between patients and controls (P=0.52). Con— clusions: These results indicated that genotype and allele frequencies of CTLA—4 gene +49 A/G polymorphism were not statistically significant different between bladder cancer patients and con— trol groups.
Cytotoxic T—lymphocyte antigen (CTLA—4) is member of the im— munoglobulin superfamily. This stimulator molecule is expressed by active cells. Recent studies have determined that dysfunction of CTLA—4 antigen leads to various diseases (Behçet's disease, diabetes, Graves' disease and systemic lupus erythematosus). It has also been suggested that there may be relationship between the CTLA—4 gene and various cancers (breast cancer, osteosarcoma, and cervical cancer). In this study, It was investigated whether the CTLA—4 gene +49 A/G (rs231775) polymorphism could be assessed as risk factor for bladder cancer patients. Material and Methods: This study included 69 patients with bladder cancer (62.07 10.48 years) with similar age distribution and 149 healthy control (61.54 14.43 years). Genotypes were determined by the polymerase chain reaction restriction fragment length polymorphism (PCR—RFLP) method. Data was analysed using the Chi—square test and Hardy—Weinberg test. The Hardy—Weinberg equilib— rium test was used to test the distributions of genotype frequency. Results: AA genotype was found in 41 (60%, in patients), 81 (55%, in control), AG genotype 23 (33%), 54 (36%) and GG genotype (7%), 14 (9%) respectively in patients with bladder cancer and in healthy control groups. The frequency of GG genotype in patients was less than controls, but there was no statistically signif— icant difference in the frequencies of GG genotype between patients and controls (P=0.52). Con— clusions: These results indicated that genotype and allele frequencies of CTLA—4 gene +49 A/G polymorphism were not statistically significant different between bladder cancer patients and con— trol groups.
Açıklama
Anahtar Kelimeler
Genel ve Dahili Tıp
Kaynak
Türkiye Klinikleri Tıp Bilimleri Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
37
Sayı
1
